Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Gefitinib plus MEDI4736 in NSCLC
jRCT2080222721Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2015
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of gefitinib and durvalumab in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Primary endpoints: Safety and tolerability of gefitinib plus durvalumab, Pharmacokinetics of gefitinib plus durvalumab and 1 more. Started Jan 2015; status: completed.
02
Drugs
gefitinibdurvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080222721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222721.